Gradientech publishes Annual Report for 2024

Gradientech AB's Annual Report for 2024 has been published and is now available on the company's website.

The Annual Report for 2024 is attached to this press release and can also be downloaded at www.gradientech.se

For further information, please contact:
Sara Thorslund, PhD, CEO          
Tel: +46 736 29 35 80                  

Urban Adolfsson, CFO
Tel: + 46 708 20 72 09

About Gradientech
Gradientech is a leader in ultra-rapid antibiotic susceptibility testing, developing next-generation diagnostics for infectious disease medicine. Our product QuickMIC®, classified as a breakthrough device by the U.S. Food and Drug Administration, contributes to the effective management of sepsis patients by supporting antibiotic treatment decisions in record time. This helps save lives, reduce healthcare costs, and combat the spread of antibiotic resistance – one of our greatest global health threats. Gradientech is headquartered in Uppsala, Sweden. Visit www.gradientech.se for more information.